XML 94 R91.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and contingencies - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Apr. 20, 2017
May 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Aug. 23, 2018
Jun. 30, 2016
Other contingencies              
Useful life     7 years        
Purchase obligation     $ 6,900        
Amortization of acquired intangible asset     27,650 $ 22,877 $ 15,380    
Akcea              
Other contingencies              
Upfront licensing fee   $ 6,000   12,000      
Milestone, potential achievements, regulatory approval     4,000        
Collaborative Arrangement | Wellcome trust limited              
Other contingencies              
Development milestone payment obligations     $ 22,400       $ 800
Non-collaborative Arrangement Transactions | Marathon Pharmaceuticals, LLC              
Other contingencies              
Development milestone payment obligations $ 50,000            
Non-collaborative Arrangement Transactions | Akcea              
Other contingencies              
Useful life     10 years        
Milestone, potential achievements, regulatory approval   $ 6,000 $ 4,000        
Emflaza asset acquisition              
Other contingencies              
Emflaza rights $ 148,373            
Milestone, potential achievements, regulatory approval     27,100 $ 14,400      
Marathon Pharmaceuticals, LLC              
Other contingencies              
Development milestone payment obligations     11,400        
Agilis              
Other contingencies              
Development milestone payment obligations     40,000     $ 40,000  
Agilis | Non-collaborative Arrangement Transactions              
Other contingencies              
Development milestone payment obligations     40,000     $ 40,000  
Maximum | Akcea              
Other contingencies              
Milestone, potential achievements, regulatory approval     4,000        
Maximum | Agilis              
Other contingencies              
Development milestone payment obligations     60,000        
Priority review voucher amount     535,000        
Net sales milestones     $ 150,000        
Percentage of annual net sales     6.00%        
Maximum | BioElectron              
Other contingencies              
Development milestone payment obligations     $ 200,000        
Minimum | Agilis              
Other contingencies              
Percentage of annual net sales     2.00%        
Intellectual Property              
Other contingencies              
Accumulated amortization     $ 65,900        
Intellectual Property | Marathon Pharmaceuticals, LLC              
Other contingencies              
Useful life 7 years